324 related articles for article (PubMed ID: 34799081)
1. [Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M
Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
3. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
4. A decade of clinical development of PARP inhibitors in perspective.
Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS
Ann Oncol; 2019 Sep; 30(9):1437-1447. PubMed ID: 31218365
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
7. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
Hilmi M; Neuzillet C
Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
[No Abstract] [Full Text] [Related]
8. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination proficiency in ovarian and breast cancer patients.
Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
[TBL] [Abstract][Full Text] [Related]
11. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
15. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M; Rodrigues M
Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
[No Abstract] [Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract][Full Text] [Related]
19. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Papadimitriou M; Mountzios G; Papadimitriou CA
Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
[TBL] [Abstract][Full Text] [Related]
20. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]